Summary

We believe MultiStem failed its phase 2 trial in ARDS.

We are highly suspicious Athersys’ “highly relevant” designation from BARDA is meaningful.

Healios KK has indicated its ARDS trial won’t be completed until mid-2021.

We believe more promising ARDS therapies are on the horizon.

Given MultiStem’s history of trial failures, we are short Athersys.